Literature DB >> 21147985

Ligand-directed trafficking of the δ-opioid receptor in vivo: two paths toward analgesic tolerance.

Amynah A A Pradhan1, Wendy Walwyn, Chihiro Nozaki, Dominique Filliol, Eric Erbs, Audrey Matifas, Christopher Evans, Brigitte L Kieffer.   

Abstract

δ-Opioid receptors are G-protein-coupled receptors that regulate nociceptive and emotional responses. It has been well established that distinct agonists acting at the same G-protein-coupled receptor can engage different signaling or regulatory responses. This concept, known as biased agonism, has important biological and therapeutic implications. Ligand-biased responses are well described in cellular models, however, demonstrating the physiological relevance of biased agonism in vivo remains a major challenge. The aim of this study was to investigate the long-term consequences of ligand-biased trafficking of the δ-opioid receptor, at both the cellular and behavioral level. We used δ agonists with similar binding and analgesic properties, but high [SNC80 ((+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide)]- or low [ARM390 (N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide)]-internalization potencies. As we found previously, a single SNC80-but not ARM390-administration triggered acute desensitization of the analgesic response in mice. However, daily injections of either compound over 5 d produced full analgesic tolerance. SNC80-tolerant animals showed widespread receptor downregulation, and tolerance to analgesic, locomotor and anxiolytic effects of the agonist. Hence, internalization-dependent tolerance developed, as a result of generalized receptor degradation. In contrast, ARM390-tolerant mice showed intact receptor expression, but δ-opioid receptor coupling to Ca²+ channels was abolished in dorsal root ganglia. Concomitantly, tolerance developed for agonist-induced analgesia, but not locomotor or anxiolytic responses. Therefore, internalization-independent tolerance was produced by anatomically restricted adaptations leading to pain-specific tolerance. Hence, ligand-directed receptor trafficking of the δ-opioid receptor engages distinct adaptive responses, and this study reveals a novel aspect of biased agonism in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21147985      PMCID: PMC3086517          DOI: 10.1523/JNEUROSCI.3748-10.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  47 in total

1.  Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Sarah T Kaminsky; Kenner C Rice; John R Traynor; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-07-13       Impact factor: 4.030

Review 2.  Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure.

Authors:  Michael H Ossipov; Josephine Lai; Tamara King; Todd W Vanderah; Frank Porreca
Journal:  Biopolymers       Date:  2005       Impact factor: 2.505

3.  Induction of delta opioid receptor function by up-regulation of membrane receptors in mouse primary afferent neurons.

Authors:  Wendy Walwyn; Nigel T Maidment; Matthew Sanders; Christopher J Evans; Brigitte L Kieffer; Tim G Hales
Journal:  Mol Pharmacol       Date:  2005-08-31       Impact factor: 4.436

4.  Morphine and pain-related stimuli enhance cell surface availability of somatic delta-opioid receptors in rat dorsal root ganglia.

Authors:  Louis Gendron; Anna Lisa Lucido; Françoise Mennicken; Dajan O'Donnell; Jean-Pierre Vincent; Thomas Stroh; Alain Beaudet
Journal:  J Neurosci       Date:  2006-01-18       Impact factor: 6.167

5.  RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia.

Authors:  Frédéric Simonin; Martine Schmitt; Jean-Paul Laulin; Emilie Laboureyras; Jack H Jhamandas; David MacTavish; Audrey Matifas; Catherine Mollereau; Patrick Laurent; Marc Parmentier; Brigitte L Kieffer; Jean-Jacques Bourguignon; Guy Simonnet
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-03       Impact factor: 11.205

6.  A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80.

Authors:  Elizabeth L Gallantine; Theo F Meert
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-07       Impact factor: 4.080

7.  Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization.

Authors:  Li He; Jamie Fong; Mark von Zastrow; Jennifer L Whistler
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

8.  Neuropathic pain is enhanced in delta-opioid receptor knockout mice.

Authors:  Xavier Nadal; Josep-Eladi Baños; Brigitte L Kieffer; Rafael Maldonado
Journal:  Eur J Neurosci       Date:  2006-02       Impact factor: 3.386

9.  Delta opioid receptor ligands modulate anxiety-like behaviors in the rat.

Authors:  Shane A Perrine; Brian A Hoshaw; Ellen M Unterwald
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

10.  In vivo delta opioid receptor internalization controls behavioral effects of agonists.

Authors:  Amynah A A Pradhan; Jérôme A J Becker; Grégory Scherrer; Petra Tryoen-Toth; Dominique Filliol; Audrey Matifas; Dominique Massotte; Claire Gavériaux-Ruff; Brigitte L Kieffer
Journal:  PLoS One       Date:  2009-05-01       Impact factor: 3.240

View more
  68 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Functional selectivity in GPCR heterocomplexes.

Authors:  J González-Maeso; S C Sealfon
Journal:  Mini Rev Med Chem       Date:  2012-08       Impact factor: 3.862

Review 3.  Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.

Authors:  Claire Gavériaux-Ruff; Brigitte Lina Kieffer
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

4.  Endocytic profiles of δ-opioid receptor ligands determine the duration of rapid but not sustained cAMP responses.

Authors:  Hanieh Bagheri Tudashki; Derek N Robertson; Peter W Schiller; Graciela Pineyro
Journal:  Mol Pharmacol       Date:  2013-10-30       Impact factor: 4.436

5.  β2-Adrenoceptor-mediated regulation of glucose uptake in skeletal muscle--ligand-directed signalling or a reflection of system complexity?

Authors:  Bronwyn A Evans; Dana S Hutchinson; Roger J Summers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-09       Impact factor: 3.000

6.  The δ-opioid receptor positive allosteric modulator BMS 986187 is a G-protein-biased allosteric agonist.

Authors:  M Alexander Stanczyk; Kathryn E Livingston; Louise Chang; Zara Y Weinberg; Manojkumar A Puthenveedu; John R Traynor
Journal:  Br J Pharmacol       Date:  2019-04-14       Impact factor: 8.739

7.  Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats.

Authors:  S Stevens Negus; Marisa B Rosenberg; Ahmad A Altarifi; Robert H O'Connell; John E Folk; Kenner C Rice
Journal:  J Pain       Date:  2012-03-15       Impact factor: 5.820

8.  In vivo visualization of delta opioid receptors upon physiological activation uncovers a distinct internalization profile.

Authors:  Lauren Faget; Eric Erbs; Julie Le Merrer; Gregory Scherrer; Audrey Matifas; Nadia Benturquia; Florence Noble; Marion Decossas; Marc Koch; Pascal Kessler; Jean-Luc Vonesch; Yannick Schwab; Brigitte L Kieffer; Dominique Massotte
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

9.  δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice.

Authors:  Amynah A Pradhan; Monique L Smith; Jekaterina Zyuzin; Andrew Charles
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

10.  Mapping GPR88-Venus illuminates a novel role for GPR88 in sensory processing.

Authors:  Aliza T Ehrlich; Meriem Semache; Julie Bailly; Stefan Wojcik; Tanzil M Arefin; Christine Colley; Christian Le Gouill; Florence Gross; Viktoriya Lukasheva; Mireille Hogue; Emmanuel Darcq; Laura-Adela Harsan; Michel Bouvier; Brigitte L Kieffer
Journal:  Brain Struct Funct       Date:  2017-11-06       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.